Skip Navigation


JAC Advance Access originally published online on July 22, 2005
Journal of Antimicrobial Chemotherapy 2005 56(3):470-480; doi:10.1093/jac/dki248
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
56/3/470    most recent
dki248v2
dki248v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (64)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Pankey, G. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Pankey, G. A.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2005. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved. For Permissions, please e-mail: journals.permissions@oupjournals.org

Review

Tigecycline

George A. Pankey*

Infectious Diseases Research, Ochsner Clinic Foundation LT 7S, 1514 Jefferson Highway, New Orleans, LA 70121-2483, USA

* Tel: +1-504-842-4005; Fax: +1-504-842-5433; E-mail: gpankey{at}ochsner.org

New antimicrobial agents are urgently needed for clinical use due to the increasing prevalence and spread of multidrug-resistant bacteria that are commonly responsible for serious and life-threatening diseases. The need to develop new agents that effectively overcome existing mechanisms of resistance displayed by bacteria resistant to currently available drugs has become paramount. Tigecycline, the first in a new class of antimicrobials, the glycylcyclines, is an analogue of minocycline with additional properties that negate most mechanisms mediating resistance to the tetracyclines. In vitro testing has revealed that tigecycline has activity against vancomycin-resistant enterococci, methicillin-resistant Staphylococcus aureus, penicillin-resistant Streptococcus pneumoniae and many species of multidrug-resistant Gram-negative bacteria, although resistance to tigecycline by Pseudomonas aeruginosa and reduced susceptibility among Proteus species do occur. Tigecycline is being evaluated in multicentre Phase III clinical trials for therapy of many serious and life-threatening infections in which multidrug-resistant bacterial organisms may be found. Tigecycline appears to hold promise as a novel expanded spectrum antibiotic.

Keywords: glycylcyclines , resistance , in vitro susceptibility , new antibiotics


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 J Antimicrob ChemotherHome page
D. Curcio
Off-label use of antibiotics in hospitalized patients: focus on tigecycline
J. Antimicrob. Chemother., December 1, 2009; 64(6): 1344 - 1346.
[Full Text] [PDF]

Home page
 J Antimicrob ChemotherHome page
T. Kelesidis, D. E. Karageorgopoulos, I. Kelesidis, and M. E. Falagas
Tigecycline for the treatment of multidrug-resistant Enterobacteriaceae: a systematic review of the evidence from microbiological and clinical studies
J. Antimicrob. Chemother., November 1, 2008; 62(5): 895 - 904.
[Abstract] [Full Text] [PDF]

Home page
 Antimicrob. Agents Chemother.Home page
R. Fernandez-Roblas, N. Z. Martin-de-Hijas, A. I. Fernandez-Martinez, D. Garcia-Almeida, I. Gadea, and J. Esteban
In Vitro Activities of Tigecycline and 10 Other Antimicrobials against Nonpigmented Rapidly Growing Mycobacteria
Antimicrob. Agents Chemother., November 1, 2008; 52(11): 4184 - 4186.
[Abstract] [Full Text] [PDF]

Home page
 Journal of Pharmacy PracticeHome page
J. A. Starr, G. W. Fox, and J. K. Clayton
Streptococcus pneumoniae: An Update on Resistance Patterns in the United States
Journal of Pharmacy Practice, October 1, 2008; 21(5): 363 - 370.
[Abstract] [PDF]

Home page
 J Antimicrob ChemotherHome page
A. P. MacGowan
Tigecycline pharmacokinetic/pharmacodynamic update
J. Antimicrob. Chemother., September 1, 2008; 62(suppl_1): i11 - i16.
[Abstract] [Full Text] [PDF]

Home page
 J Antimicrob ChemotherHome page
D. E. Karageorgopoulos, T. Kelesidis, I. Kelesidis, and M. E. Falagas
Tigecycline for the treatment of multidrug-resistant (including carbapenem-resistant) Acinetobacter infections: a review of the scientific evidence
J. Antimicrob. Chemother., July 1, 2008; 62(1): 45 - 55.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Microbiol.Home page
D. Curcio
Treatment of Recurrent Urosepsis with Tigecycline: a Pharmacological Perspective
J. Clin. Microbiol., May 1, 2008; 46(5): 1892 - 1893.
[Full Text] [PDF]

Home page
 J Antimicrob ChemotherHome page
J. Vouillamoz, P. Moreillon, M. Giddey, and J. M. Entenza
In vitro activities of tigecycline combined with other antimicrobials against multiresistant Gram-positive and Gram-negative pathogens
J. Antimicrob. Chemother., February 1, 2008; 61(2): 371 - 374.
[Abstract] [Full Text] [PDF]

Home page
 J Antimicrob ChemotherHome page
A. P. Zavascki, L. Z. Goldani, J. Li, and R. L. Nation
Polymyxin B for the treatment of multidrug-resistant pathogens: a critical review
J. Antimicrob. Chemother., December 1, 2007; 60(6): 1206 - 1215.
[Abstract] [Full Text] [PDF]

Home page
 J Antimicrob ChemotherHome page
A. Deplano, O. Denis, C. Nonhoff, F. Rost, B. Byl, F. Jacobs, V. Vankerckhoven, H. Goossens, and M. J. Struelens
Outbreak of hospital-adapted clonal complex-17 vancomycin-resistant Enterococcus faecium strain in a haematology unit: role of rapid typing for early control
J. Antimicrob. Chemother., October 1, 2007; 60(4): 849 - 854.
[Abstract] [Full Text] [PDF]

Home page
 J Antimicrob ChemotherHome page
J. Y. Song, S. Y. Kee, I. S. Hwang, Y. B. Seo, H. W. Jeong, W. J. Kim, and H. J. Cheong
In vitro activities of carbapenem/sulbactam combination, colistin, colistin/rifampicin combination and tigecycline against carbapenem-resistant Acinetobacter baumannii
J. Antimicrob. Chemother., August 1, 2007; 60(2): 317 - 322.
[Abstract] [Full Text] [PDF]

Home page
 J Antimicrob ChemotherHome page
D. Curcio and F. Fernandez
Acinetobacter spp. susceptibility to tigecycline: a worldwide perspective
J. Antimicrob. Chemother., August 1, 2007; 60(2): 449 - 450.
[Full Text] [PDF]

Home page
 J. Clin. Microbiol.Home page
D. Curcio, F. Fernandez, R. N. Jones, M. J. Ferraro, L. B. Reller, P. C. Schreckenberger, and H. S. Sader
Tigecycline Disk Diffusion Breakpoints of Acinetobacter spp.: a Clinical Point of View
J. Clin. Microbiol., June 1, 2007; 45(6): 2095 - 2096.
[Full Text] [PDF]

Home page
 J Antimicrob ChemotherHome page
K. A. Rodvold, M. H. Gotfried, M. Cwik, J. M. Korth-Bradley, G. Dukart, and E. J. Ellis-Grosse
Serum, tissue and body fluid concentrations of tigecycline after a single 100 mg dose
J. Antimicrob. Chemother., December 1, 2006; 58(6): 1221 - 1229.
[Abstract] [Full Text] [PDF]

Home page
 Antimicrob. Agents Chemother.Home page
C. E. Nord, E. Sillerstrom, and E. Wahlund
Effect of tigecycline on normal oropharyngeal and intestinal microflora.
Antimicrob. Agents Chemother., October 1, 2006; 50(10): 3375 - 3380.
[Abstract] [Full Text] [PDF]

Home page
 Antimicrob. Agents Chemother.Home page
O. Denis, A. Deplano, C. Nonhoff, M. Hallin, R. De Ryck, R. Vanhoof, R. De Mendonca, and M. J. Struelens
In Vitro Activities of Ceftobiprole, Tigecycline, Daptomycin, and 19 Other Antimicrobials against Methicillin-Resistant Staphylococcus aureus Strains from a National Survey of Belgian Hospitals.
Antimicrob. Agents Chemother., August 1, 2006; 50(8): 2680 - 2685.
[Abstract] [Full Text] [PDF]

Home page
 Am J Health Syst PharmHome page
N. Kasbekar
Tigecycline: A new glycylcycline antimicrobial agent.
Am. J. Health Syst. Pharm., July 1, 2006; 63(13): 1235 - 1243.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.